Treatment of uveal melanoma: where are we now?

252Citations
Citations of this article
251Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Uveal melanoma, a rare subset of melanoma, is the most common primary intraocular malignancy in adults. Despite effective primary therapy, nearly 50% of patients will develop metastatic disease. Outcomes for those with metastatic disease remain dismal due to a lack of effective therapies. The unique biology and immunology of uveal melanoma necessitates the development of dedicated management and treatment approaches. Ongoing efforts seek to optimize the efficacy of targeted therapy and immunotherapy in both the adjuvant and metastatic setting. This review provides a comprehensive, updated overview of disease biology and risk stratification, the management of primary disease, options for adjuvant therapy, and the current status of treatment strategies for metastatic disease.

Cite

CITATION STYLE

APA

Yang, J., Manson, D. K., Marr, B. P., & Carvajal, R. D. (2018, January 1). Treatment of uveal melanoma: where are we now? Therapeutic Advances in Medical Oncology. SAGE Publications Inc. https://doi.org/10.1177/1758834018757175

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free